Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis

INTRODUCTION: Lumacaftor/ivacaftor (LUM/IVA) has been shown to improve clinical outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with forced expiratory volume in 1 s (FEV(1)) % pred >40%. We assessed the clinical utility of LUM/IVA in all eligible adult CF patients with FEV(1) %...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Susannah J., Keating, Dominic, Williams, Elyssa, Paul, Eldho, Borg, Brigitte M., Finlayson, Felicity, Button, Brenda M., Wilson, John W., Kotsimbos, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861032/
https://www.ncbi.nlm.nih.gov/pubmed/33569502
http://dx.doi.org/10.1183/23120541.00203-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861032/
https://www.ncbi.nlm.nih.gov/pubmed/33569502
http://dx.doi.org/10.1183/23120541.00203-2020

Ejemplares similares